CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,262 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01444456
NCT01444456N/ACompleted

Electronic Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia: An International Prospective Observational Study (eAQUA)

Amgen·observational·Posted Sep 30, 2011·Updated Mar 20, 2017

In Brief

An observational study for Anemia and 13 related conditions. Completed, enrolled 1,262 participants across 117 sites in 9 countries.

Detailed Summary

This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal, pancreatic, esophageal or gastric) and who are receiving darbepoetin alfa (Aranesp®) or other erythropoiesis-stimulating agent (ESA) to treat symptomatic anaemia. Quality of Life will be assessed electronically with the aim of estimating improvement in quality of life for those patients receiving darbepoetin alfa (Aranesp®) who also have an increase in haemoglobin (Hb) of ≥1 g/dL

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Belgium, France, Germany, Greece, Italy, Netherlands, Poland, Romania
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 30, 2011
Enrollment StartOct 1, 2011
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.8 years ago